FDA Approves Extended-Release Version of HIV Drug
April 6, 2011
The Food and Drug Administration has approved an extended-release form of the HIV drug nevirapine. Boehringer Ingelheim Pharmaceuticals' Viramune XR is a 400 mg tablet taken once daily; the earlier version required twice-daily dosing. "Viramune XR is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults," FDA said. Patients needing financial assistance to access the drug are asked to telephone 800-556-8317 or visit www.RxHope.com. To read FDA's statement, visit www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm248800.htm.
04.04.2011; Rinker Buck
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)